Risk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis

@article{Alqudah2018RiskOP,
  title={Risk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis},
  author={Abdelrahim Alqudah and Mark McKinley and Ross McNally and U. M. Graham and Chris J. Watson and Timothy J. Lyons and Lana McClements},
  journal={Diabetic Medicine},
  year={2018},
  volume={35},
  pages={160 - 172}
}
AIMS To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy. [...] Key MethodMETHODS A search was conducted of the Medline, EMBASE, Web of Science and Scopus databases. Both randomized controlled trials and prospective observational cohort studies of metformin treatment vs. placebo/control or insulin either prior to or during pregnancy were selected.Expand

Paper Mentions

Interventional Clinical Trial
This is an open label, randomized control trial (RCT) in which high risk for pre-eclampsia pregnant subjects will be randomly assigned to either an intervention group (metformin 1 gm… Expand
ConditionsEclampsia, High Risk Pregnancy, Preeclampsia, (+1 more)
InterventionDrug
Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta‐analysis of randomized trials
TLDR
Whether metformin use is associated with the incidence of hypertensive disorders of pregnancy (HDP) is determined by a systematic review and meta‐analysis of randomized trials. Expand
Meta-analysis suggests that metformin may reduce pre-eclampsia compared with insulin use during pregnancy
  • D. Feig
  • Medicine
  • BMJ Evidence-Based Medicine
  • 2018
TLDR
In the two randomised controlled trials (RCTs) of metformin use in obese women, one showed a significant reduction in pre-eclampsia while the other showed no difference. Expand
Real‐world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register
TLDR
In Australia's Northern Territory, Indigenous mothers account for 33% of births and have high rates of hyperglycemia in pregnancy, and the use of metformin is common. Expand
Prevention of preeclampsia.
TLDR
This review focuses on the main therapeutic agents evaluated or in use for preeclampsia prevention, and focuses on aspirin and other aspirin-like agents currently in use. Expand
Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis
TLDR
Metformin for any indication during pregnancy is associated with lower GWG and a modest reduced risk of pre-eclampsia, but increased gastrointestinal side-effects compared to other treatments. Expand
Effect of metformin on biomarkers of placental- mediated disease: A systematic review and meta-analysis.
TLDR
Findings show that metformin mediates several molecular pathways implicated in the pathogenesis of pre-eclampsia and intrauterine growth retardation and has exciting potential as a therapeutic, as well as preventative, agent in the treatment of PMD, which warrants further investigation. Expand
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome
TLDR
The existing evidence around metformin use is summarized both during the preconceptual period and during pregnancy, in relation to reproductive outcomes, and the evidence remains equivocal regarding its efficacy both in optimizing fertility and pregnancy outcomes. Expand
Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial
TLDR
This trial suggests that extended release metformin can prolong gestation in women with preterm pre-eclampsia, although further trials are needed. Expand
Biochemical Dysregulation of Pre-Eclampsia and Gestational Diabetes Mellitus
TLDR
The altered physiological parameters, dysregulation of potential protein biomarkers and DNA-related changes (mutations, methylations, miRNAs) will be combined in this review to explore possible underlying mechanisms of pre-eclampsia and gestational diabetes mellitus. Expand
Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.
TLDR
Metformin exposure was associated with a decreased risk of composite hypertensive disorders of pregnancy in patients with pregestational type 2 diabetes, and data suggest that there may be benefit to metformin administration beyond glycemic control in this patient population. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes
TLDR
There are no contemporary cohorts examining pregnancy outcomes in women with type 2 diabetes (T2D) in Australia and the chances of complications during pregnancy are low. Expand
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study
TLDR
The use of metformin in the treatment of gestational diabetes should be considered, according to a prospective randomised study carried out in Finland. Expand
Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin
We compared metformin with insulin as treatment of gestational diabetes mellitus (GDM). Furthermore, we aimed to characterize metformin‐treated patients needing additional insulin to achieveExpand
Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study
  • S. Khattab, I. Mohsen, +5 authors M. A. Youssef
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2011
TLDR
Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women. Expand
First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis.
TLDR
There is currently no evidence that metformin is associated with an increased risk of major birth defects in women affected by PCOS and treated during the first trimester, but larger ad hoc studies are warranted in order to definitely confirm the safety and efficacy of this drug in pregnancy. Expand
Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort
TLDR
The ability to predict pre-eclampsia in healthy nulliparous women using clinical phenotype is modest and requires external validation in other populations. Expand
Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial
Summary Background Results of several trials of antioxidant use during pregnancy have not shown a reduction in pre-eclampsia, but the effect in women with diabetes is unknown. We aimed to assessExpand
Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.
TLDR
Metformin treatment from first trimester to delivery did not reduce pregnancy complications in PCOS and women in the metformin group gained less weight during pregnancy compared with those in the placebo group. Expand
Predictors of Preeclampsia in Women in the Metformin in Gestational Diabetes(Mig) Study
TLDR
Treatment allocation and BMI were not associated with risk of PE and the strongest positive predictors for PE were Polynesian ethnicity and personal or family history of PE, and when further adjusted for HbA1c or early pregnancy BMI, these variables remained significant. Expand
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia.
  • Yogev, Chen, +12 authors Rogers
  • Medicine
  • American journal of obstetrics and gynecology
  • 2010
TLDR
Analysis of associations of fasting C-peptide, body mass index (BMI), and maternal glucose with the risk of preeclampsia in a multicenter multinational study indicates strong, independent associations offasting C- peptide and BMI with preeClampsia. Expand
...
1
2
3
4
5
...